Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer

NCT02066532 is registered in ClinicalTrials.gov with Dawn L. Hershman as lead sponsor.

NCT NCT02066532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02066532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
Lead sponsor
Dawn L. Hershman
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2014
Completion date
October 14, 2020
Enrollment
32 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast carcinoma, her-2 positive breast cancer, metastatic breast cancer